In September of 2005, Eunoe Inc was acquired by Integra LifeSciences. Eunoe, previously known as CSFluids, was founded by a team of Stanford University professors. Eunoe Inc. has developed and is testing a proprietary device-based treatment for Alzheimer´s disease, to improve clearance of neurotoxins that may be significant in the progression of Alzheimer´s disease. The device is the COGNIShunt® System, a cerebrospinal fluid shunt similar but not identical to shunts used for the treatment of children and adults with hydrocephalus. The COGNIShunt has been engineered specifically to provide a low flow of cerebrospinal fluid (CFS) in individuals without hydrocephalus. It is designed to improve CSF clearance without the over drainage of CSF that can occur with hydrocephalus shunts. The hypothesis is that impaired clearance or diminished production of CSF leads to stagnation of CSF, resulting in accumulation of toxic proteins and inflammatory mediators in the brain
